LakeShore Biopharma Co., Ltd
LSB · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | – | – | $135,527 | $168,706 |
| % Growth | – | – | -19.7% | – |
| Cost of Goods Sold | – | – | $101,119 | $34,899 |
| Gross Profit | – | – | $34,408 | $133,807 |
| % Margin | – | – | 25.4% | 79.3% |
| R&D Expenses | – | – | $58,809 | $68,244 |
| G&A Expenses | – | – | $1,804 | $78,233 |
| SG&A Expenses | – | – | $53,062 | $149,720 |
| Sales & Mktg Exp. | – | – | $51,404 | $71,342 |
| Other Operating Expenses | – | – | $103,682 | $0 |
| Operating Expenses | – | – | $215,554 | $217,964 |
| Operating Income | – | – | -$181,146 | -$81,428 |
| % Margin | – | – | -133.7% | -48.3% |
| Other Income/Exp. Net | – | – | -$13,751 | -$3,525 |
| Pre-Tax Income | – | – | -$194,897 | -$84,954 |
| Tax Expense | – | – | -$13,719 | -$7,189 |
| Net Income | – | – | -$181,410 | -$77,770 |
| % Margin | – | – | -133.9% | -46.1% |
| EPS | – | – | -1.81 | -0.85 |
| % Growth | – | – | -112.9% | – |
| EPS Diluted | – | – | -1.81 | -0.85 |
| Weighted Avg Shares Out | – | – | 99,991 | 93,058 |
| Weighted Avg Shares Out Dil | – | – | 99,991 | 93,058 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | – | $0 | $31 |
| Interest Expense | – | – | $23,636 | $8,353 |
| Depreciation & Amortization | – | – | $10,546 | $9,154 |
| EBITDA | – | – | -$82,617 | -$72,354 |
| % Margin | – | – | -61% | -42.9% |